Drug Trial Radar · NCT07124936
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Aug 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
97
Planned (sponsor's estimate)
Start
Jul 30, 2025
Primary completion
Oct 26, 2027
Study completion Oct 25, 2029
Sponsor
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this phase 1b/2 study is to evaluate the safety, tolerability, and antitumor activity of HDM2005 in combination with standard of care in participants with diffuse large B-cell lymphoma. This study will include two arms: Cohort A (HDM2005 + R-GemOx) will enroll participants with relapsed/refractory DLBCL. Cohort B (HDM2005 + R-CHP) will enroll participants with untreated DLBCL. The study will consist of two parts: dose-escalation part and dose-expansion part.
Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
HDM2005Drug
HDM2005 will be administered as an intravenous injection.
Rituximab or Rituximab biosimilarDrug
Rituximab or Rituximab biosimilar will be administered as an intravenous injection.
GemcitabineDrug
Gemcitabine will be administered as an intravenous injection.
OxaliplatinDrug
Oxaliplatin will be administered as an intravenous injection.
CyclophosphamideDrug
Cyclophosphamide will be administered as an intravenous injection.
DoxorubicinDrug
Doxorubicin will be administered as an intravenous injection.
PrednisoneDrug
Prednisone will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who experience dose-limiting toxicities (DLTs) in dose-escalation partTime frame: Up to ~3 weeks
- Number of participants who experience adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs) in dose-escalation partTime frame: Up to ~54 months
- Complete response (CR) rate in dose-expansion partTime frame: Up to ~30 months
- RP2D of HDM2005Time frame: Up to ~30 months
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Not yet recruiting
The Affiliated Tumor Hospital of Guangxi Medical University
Nanning, Guangxi, China · Not yet recruiting
Affiliated Tumor Hospital of Harbin Medical University
Harbin, Heilongjiang, China · Not yet recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Not yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
HunanCancer Hospital
Changsha, Hunan, China · Not yet recruiting
Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Not yet recruiting
The First Affiliated Hospital Of Nanchang University
Nanchang, Jiangxi, China · Not yet recruiting
The first hospital of Jilin University
Changchun, Jilin, China · Not yet recruiting
Shengjing Hospital Affiliated to China Medical University
Shenyang, Liaoning, China · Not yet recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China · Not yet recruiting
Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital)
Jinan, Shandong, China · Not yet recruiting
Shanxi Cancer Hospital
Taiyuan, Shanxi, China · Not yet recruiting
West China Hospital,Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
The Second Affiliated Hospital of Kunming Medical UniversityThe Second Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China · Active not recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Not yet recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.